natgillin/translations-raw huggingface dataset:
is selected from halogeno, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, amino, carboxy, carbamoyl, and sulphamoyl; or is a group of the formula: 
je halogeno, trifluorometil, trifluorometoksi, cijano, hidroksi, amino, karboksi, karbamoil, sulfamoil, ili R6 je skupina formule:
The method of claim 1, wherein there is a post-administration reduction in absolute basophil count of at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, or at least 70 basophils/mm3. 
Protutijelo za uporabu prema bilo kojem od zahtjeva 1-4, naznačeno time da postoji smanjenje apsolutnog broja bazofila nakon davanja od barem 5, barem 10, barem 15, barem 20, barem 25, pri barem 30, barem 35, barem 40, najmanje 45, barem 50, barem 55, barem 60, barem 65 ili barem 70 bazofila/mm".
The compound of claim 1 for use according to claim 2 wherein the disease or condition is systemic lupus erthematosus (SLE), lupus nephritis, rheumatoid arthritis, psoriasis, atopic dermatitis, gout, cryopyrin-associated periodic syndrome (CAPS), diffuse large B cell lymphoma (DLBCL), chronic kidney disease or acute kidney injury, chronic obstructive pulmonary disorder (COPD), asthma or bronchospasm. 
Spoj u skladu s patentnim zahtjevom 1 namijenjen upotrebi u skladu s patentnim zahtjevom 2, naznačen time što je bolest ili stanje sistemni eritematozni lupus (SLE), lupozni nefritis, reumatoidni artritis, psorijaza, atopični dermatitis, giht, periodični sindrom povezan s kriopirinom (CAPS), difuzni limfom velikih B-stanica (DLBCI), kronična bolest bubrega ili akutna ozljeda bubrega, kronični opstruktivni plućni poremećaj (COPD), astma ili broncospazam.
A kit comprising as separate components, the TH-1 adjuvant and the VZV gE antigen as defined for any preceding claim, suitable for extemporaneous preparation of a vaccine composition, for use in the prevention or amelioration of shingles and/or post herpetic neuralgia in a population of individuals older than 50 and immunocompromised individuals. 
Komplet koji kao odvojene komponente sadrži adjuvans TH-1 i antigen VZV gE u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je pogodan za improviziranu priprava cjepivnog pripravka, namijenjenog upotrebi u sprječavanju ili ublažavanju zone i/ili postherpetične neuralgije.
reaction of C with phenyl fluorenyl bromide to create compound 3, or with benzyl bromide to create compound 3 *. 
(c) reakciju C s fenil fluorenil bromidom kako bi se dobio spoj 3 ili s benzil bromidom kako bi se dobio spoj So kk pa A
The first antigen binding protein according to claim 3 or claim 4, wherein said second antigen binding protein is an antibody comprising a full-length heavy chain and a full-length light chain, wherein the full-length heavy chain and full-length light chain comprise the amino acid sequences set forth below: 
Protutijelo u skladu s patentnim zahtjevom 2 ili patentnim zahtjevom 5, naznačeno time što navedeno protutijelo ima puni teški lanac i puni laki lanac, gdje navedeni puni teški lanac i puni laki lanac imaju aminokiselinske sljedove iznijete niže:
Equal amounts of diethyl ether and water were added and the product extracted. 
Dodane su jednake količine dietil etera i vode i produkt je ekstrahiran.
The method according to claim 9, wherein the polypeptide further comprises epitopes not containing cancer specific somatic mutations which are expressed by cancer cells. 
Individualizirano cjepivo protiv raka za uporabu prema patentnom zahtjevu 7, naznačeno time, što rekombinantni poliepitopski polipeptid uključuje još 1 epitope koji ne sadrže za rak specifične somatske mutacije koje se eksprimiraju u stanicama raka.
Leucine (L) at heavy chain amino acid position 67; and 
(d) leukin (L) na aminokiselinskoj poziciji 67 jakog lanca; i
The recommended international non-proprietary names is ALDESLEUKIN, and a formulation is marketed by Chiron Corporation under the trade name PROLEUKIN™. The United States FDA has approved PROLEUKIN™ IL-2 for use in the treatment of adults with metastatic renal cell carcinoma (metastatic RCC) or metastatic melanoma. 
Preporučeno međunarodno zakonom nezaštićeno ime je ALDESLEUKIN i formulaciju daje na tržište Chiron Corporation pod trgovačkim imenom PROLEUKINTM, FDA Sjedinjenih država odobrila je PROLEUKINTM IL-2 za uporabu u liječenju odraslih s metastatskim karcinomom bubrežnih stanica (metastatski RCA) ili metastatskim melanomom.
The process according to claim 1, wherein in step d) the addition of the at least one water-soluble salt take place in a stirred reactor under stirring conditions such as to develop a laminar flow. 
Postupak prema bilo kojem od zahtjeva 1 do 17, naznačen time da se korak d) i dodavanje navedene kiseline topive u vodi poželjno odvija u reaktoru za miješanje pod uvjetima miješanja koji su potrebni da bi se razvio u osnovi laminarni tok.
The method according to claim 2, wherein the milk source is selected from the group consisting of a full fat milk, skimmed milk, semi-skimmed milk, fresh milk, recombined milk, cream, buttermilk, whey and milk containing vegetable fat. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 3 do 7, naznačen time što izvor mlijeka se bira između najmanje jednog od punomasnog mlijeka, obranog mlijeka, poluobranog mlijeka, svježeg mlijeka, rekombiniranog mlijeka, vrhnja, mlaćenice, sirutke i mlijeka koje sadrži biljnu mast.
The aryl groups can be independently mono or multiply substituted with cyano, halogen, alkyl, branched alkyl, halogenated alkyl, hydroxyl, alkyloxy, amino, alkylamino, dialkylamino, mercaptanyl, alkylmercaptanyl, alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aryl, arylalkyl, carbocycle, carbocycle-alkyl, and/or other small substitution groups. 
Bs je opcionalno supstituirani monociklički ili biciklički aril ili heteroaril, pri čemu je svaki prsten 5, 6 ili 7 člani prsten i opcionalna supstitucija je halo, cijano, C,-C4 alkil, Ci-Cg razgranati alkil, halogenirani C;-Cg alkil, hidroksil, Ci-Cg alkoksi, amino ili Ci-Cg alkilamino.
A suspension according to claim 1, characterized in that riluzole or said pharmaceutically salt or derivative thereof is in particle form. 
Suspenzija u skladu s patentnim zahtjevom 1, naznačena time što su riluzol ili navedena njegova farmaceutska sol u obliku čestica.
Compound VI is reacted with 2,2-dimethylpiperazine to obtain the compound of formula VII 
Spoj VI reagira s 2,2-dimetilpiperazinom radi dobivanja spoja formule VII je
EXAMPLE 54 was prepared according to the procedure used for EXAMPLE 53 except that piperidine-1-sulfonamide [Bioorg. 
. Spoj prema patentnom zahtjevu 13, naznačen time što se koristi za primjenu u postupku prevencije ili liječenja
The method according to claim 1, wherein the compressible fluid is contained in the drum having a diameter of at least 1.5 meter and is rotated at at least 50 RPM. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da je fluid koji se može komprimirati sadržan u bubnju čiji je promjer od najmanje 1,5 metara i okreće se pri najmanje 50 okretaja u minuti, ili poželjno pri najmanje 100 okretaja u minuti.
is SR or COR, wherein R is linear alkyl or alkenyl having from I to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, or simple or substituted aryl or heterocyclic aromatic or heterocycloalkyl radical; and May is a maytansinoid. 
je SR ili -COR, pri čemu je R linearni alkil ili alkenil s 1 do 10 atoma ugljika, razgranati ili ciklički alkil ili alkenil s 3 do 10 atoma ugljika, ili jednostavni ili supstituirani aril ili heterociklički aromatski ili heterocikloalkilni radikal; i May je majtanzinoid.
The compound or salt for use according to claim 9, wherein said an additional pharmaceutical agent is a chemotherapeutic agent. 
Spoj ili sol prema zahtjevu 48 naznačen time da navedena bolest je a mijeloproliferativni poremećaj.
The CD19xCD3 bispecific single chain antibody construct for the use of claim 1 or 2, wherein said acute lymphoblastic leukemia (ALL) is refractory to chemotherapy in patients non-eligible for allogeneic hematopoietic stem cell transplantation. 
CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što navedena akutna limfoblastična leukemija (ALI) ne reagira na kemoterapiju kod pacijenata neprikladnih za presađivanje alogenih krvotvornih matičnih stanica.
The compound according to claim 1, wherein ring B and the pyrimidine to which it is fused form a ring system selected from the group consisting of 
Spoj prema zahtjevu 1, naznačen time da prsten B i pirimidin na koji je kondenziran tvore prstenasti sustav odabran od
The aqueous pharmaceutical suspension according to claim 7, wherein the propylparaben, sodium propylparaben, or potassium propylparaben is, by weight/volume (g/100 mL), about 0.014% to about 0.048%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što propilparaben, natrij- propilparaben ili kalij-propilparaben iznosi, težinskifvolumno (g/100 ml), otprilike 0,014 % do otprilike 0,048 %.
The pharmaceutical composition for use according to claim 4, which is administered in combination with another anticancer agent selected from the group consisting of cell signal transduction inhibitors, mitosis inhibitors, alkylating agents, antimetabolites, antibiotics, growth factor inhibitors, cell cycle inhibitors, topoisomerase inhibitors, biological reaction modifiers, antihormonal agents, and antiandrogen. 
Farmaceutski pripravak za uporabu prema zahtjevu 4, naznačen time da se daje u kombinaciji s drugim antikancerogenim sredstvom odabranim iz skupine koju čine inhibitori transdukcije staničnih signala, inhibitori mitoze, alkilacijska sredstva, antimetaboliti, antibiotici, inhibitori faktora rasta, inhibitori staničnog ciklusa, inhibitori topoizomeraze, modifikatori biološke reakcije, antihormonska sredstva, te antiandrogeni.
is B-D-, where D is a linker, which is selected from: 
je B-D-, gdje D je jednostruka veza;
The presence of convulsions or tremors-twitches and stereotypies was again noted. 
Ponovno je zabilježena prisutnost konvulzija ili drhtanja-grčeva kao 1 stereotipovi.
The method of claim 1, wherein said subject has been determined to be affected with a not yet manifested disorder or at risk to develop the disorder by the presence or the absence of a surrogate marker selected from the group consisting of old age, ApoE genotype, APP genotype, PS1 genotype, isoprostanes, Tau, and phospho-Tau. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, da je kod navedenog bolesnika utvrđeno da pati od poremećaja koji se još nije manifestirao ili postoji rizik da bi mogao razviti poremećaj zbog prisutnosti ili odsutnosti surogatnog markera, pri čemu je poželjno da je navedeni surogatni marker odabran iz skupine koja obuhvaća starost, amiloidno opterećenje mozga, ApoE genotip, APP genotip, PSI genotip, razine tjelesnih tekućina Abeta peptida, izoprostan, Tau i fosfo-Tau.
The composition for use according to any one of claims 1 to 4, wherein the composition is formulated for oral administration. 
Smjesa za uporabu prema zahtjevu 1 ili 2, gdje je bolest CMT, poželjno CMTIA.
In other embodiments, the pharmaceutical composition may further comprise a peptide that consists of the amino acid sequence set forth in SEQ ID NO: 11. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1 do 6 gdje spomenuti sastav sadrži peptide koji se sastoje od slijeda aminokiselina koji je prethodno definiran u SEQ ID BR: 11.
The subject matter of claim 15, wherein the insertion site is located between the start site of E1 b-19K and the start site of E1b 55K. 
Predmetni sadržaj prema zahtjevu 15, gdje se mjesto umetanja nalazi između početnog mjesta u Elb-19K i početnog mjesta u Elb 55K.
an amplifier (102) with an adjustable gain amplifying the analog electrical signal (S1) and thereby producing an amplified signal (S2), 
- < pojačala (102) s podesivim pojačanjem koje pojačava analogni električni signal (S1) 1 time stvara pojačani signal (S2),
The article illustrated in Figure 1 also includes an optional mass or plug of tobacco 28 to contribute flavor to the aerosol. This tobacco charge 28 may be placed at the mouth end of disc 22, as shown in Figure 1, or it may be placed between glass beads 20 and disc 22. 
Proizvod koji je ilustriran na sl. 1 također uključuje opcijsku masu ili čep 28 duhana radi doprinosa mirisu aerosola, Ovaj duhanski čep 23 može se postaviti na usni kraj diska 22, kao što je prikazano na sl. 1, ili se može postaviti između staklenih perli 20 1 diska 22.
The best results were achieved, when wood was impregnated with preservative solution consisting of solution where ethanolamine was used as amine source. 
Da bi se postigli najbolji rezultati, kad se drvo impregnira s otopinom konzervansa koja se sastoji od otopine u kojoj je etanolamin upotrijebljen kao izvor amina.
deletion of an endogenous rat nucleic acid sequence, wherein the deletion ranges from about 5 kb to about 10 kb, from about 10 kb to about 20 kb, from about 20 kb to about 40 kb, from about 40 kb to about 60 kb, from about 60 kb to about 80 kb, from about 80 kb to about 100 kb, from about 100 kb to about 150 kb, from about 150 kb to about 200 kb, from about 200 kb to about 300 kb, from about 300 kb to about 400 kb, from about 400 kb to about 500 kb, from about 500 kb to about 1 Mb, from about 1 Mb to about 1.5 Mb, from about 1.5 Mb to about 2 Mb, from about 2 Mb to about 2.5 Mb, or from about 2.5 Mb to about 3 Mb; 
deleciju sekvence endogene nukleinske kiseline štakora, pri čemu je delecija u rasponu od oko 5 kb do oko 10 kb, od oko 10 kb do oko 20 kb, od oko 20 kb do oko 40 kb, od oko 40 kb do oko 60 kb, od oko 60 kb do oko 80 kb, od oko 80 kb do oko 100 kb, od oko 100 kb do oko 150 kb, od oko 150 kb do oko 200 kb, od oko 200 kb do oko 300 kb, od oko 300 kb do oko 400 kb, od oko 400 kb do oko 500 kb, od oko 500 kb do oko 1 Mb, od oko 1 Mb do oko 1,5 Mb, od oko 1,5 Mb do oko 2 Mb, od oko 2 Mb do oko 2,5 Mb, ili od oko 2,5 Mb do oko 3 Mb;
A variant according to paragraph 1, wherein said variant comprises an antibody or immunoadhesin, and wherein said Fc region is selected from the group consisting of: IgG1, IgG2, IgG3, and IgG4. 
-Antitijelo za uporabu prema zahtjevu 2, naznačeno time da navedeno antitijelo ima specifičnost za antigen odabran iz skupine koja se sastoji od: vaskularnog endotelnog faktora rasta (VEGF), faktora nekroze tumora a (TNF-a), CD25, receptora epidermalnog faktora rasta (EGFR) i IgE.
Such modifications are intended to fall within the scope of the appended claims. A method of preventing or ameliorating severe cerebral malaria in a subject infected with Plasmodium falciparum, the method comprising: (a) selecting a subject with more than 0.1% parasitemia; and (b) administering a pharmaceutical composition comprising a therapeutically effective amount of a fusion protein comprising at least one fibrinogen-like domain of angiopoietin-1 fused to an immunoglobulin Fc fragment to the subject in need thereof. 
Farmaceutski pripravak koji sadrži terapijski učinkovitu količinu modificiranog proteina angiopoietina za primjenu u metodi za sprječavanje teške cerebralne malarije kod subjekta zaraženog rodom Plasmodium, pri čemu se metoda sastoji od: (a) odabira subjekta s parazitemijom većom od 0,1 %; 1 (b) primjene farmaceutskog pripravka kod subjekta kojemu je isti potreban, naznačen time, što modificirani angiopoietin sadrži fuzijski protein koji sadrži najmanje jednu fibrinogensku domenu angiopoietina-1 spojenu s imunoglobulinskim Fc fragmentom.
The expansion joint according to claim 8, wherein the corrugated plates and the dividing member (4) are secured to one another through a binding member (8). 
Kompenzacijski spoj prema zahtjevu 8, naznačen time da su valovite ploče 1 razdjelni element (4) međusobno pričvršćeni preko veznog elementa (8).
A pharmaceutical composition comprising as active ingredient at least one compound of formula (I) as defined in any one of the claims 1 to 10 or the compound (6-Bromo-pyrazolo[1,5-a]pyrimidin-2-yl)-(3,4-dihydro-1H-isoquinolin-2-yl)-methanone or the optical isomers, pharmaceutically acceptable salts, hydrates, solvates or polymorphs thereof, together with one or more pharmaceutically acceptable excipients. 
Farmaceutski spoj koji kao aktivne tvari sadrži barem jednu of formula (I) kako su definirane bilo kojem od zahtjeva 1 do 10 ili spoj (6- bromo- pirazolo [1,5- a] pirimidin- 2- il) – (3,4- dihidro- 1H- izokvinolin- 2- il)- metanon ili njihove optičke izomere, farmaceutski prihvatljive soli, hidrate, otopine ili polimorfe, zajedno sa jednim ili više farmaceutski prihvatljivih ekscipijenata.
Brief description of the drawings 
Kratki opis crteža
A winder unit (1) in accordance with any preceding claim, wherein, in set up, the cutting wire passes through the bonding material at a position to the same side of the glazing panel as the wire winder unit. 
Jedinica za namatanje, namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što, u radnim uvjetima, žica za rezanje prolazi kroz materijal za vezanje na položaju koji je na istoj strani prozorskog panela na kojoj je i jedinica za namatanje žice.
the reduction of a compound of formula II to give a compound of formula 
GD gdje je X halogen; b. redukciju spoja formule II da se dobije spoj formule
A kit comprising the set of reaction mixtures of claim 1 . A kit comprising the substrate of claim 22 . The set of reaction mixtures of claim 1, wherein the sample is from a subject taking an immunomodulator, a subject considering taking an immunomodulator, or a subject suspected of having Progressive Multifocal Leukoencephalopathy (PML). 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je uzorak iz subjekta kojem je prepisan imunomodulator, se smatra da subjekt treba uzeti imunomodulator, ili se sumnja da subjekt ima progresivnu multifokalnu leukoencefalopatiju (PML), gdje se imunomodulator bira između terapije protiv VLA-4, terapije protiv CD2, terapije protiv CDI 1a, ili mikofenolat mofetila.
The method according to claim 22, wherein before the step of adding the Grignard reagent of the formula IX to the thiolactone of the formula VIII to obtain a compound V, about 0.8 to 1.2 equivalents of R30MgX (R30 represents a C1-8 alkyl group or a C3-7 cycloalkyl group, and X represents a halogen atom) is added to the thiolactone of the formula VIII. A method for producing a 1-thio-D-glucitol compound of the following formula I, or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt: 
Postupak prema zahtjevu 26, naznačen time da se prije koraka dodavanja Grignardovog reagensa formule IX u tiolakton formule VIII da se dobije spoj V, oko 0.8 do 1.2 ekvivalenata R*MgX (R" predstavlja C.g alkil skupinu ili C3.; cikloalkil skupinu, te X predstavlja atom halogena) dodaje u tiolakton formule VIII. Postupak dobivanja 1-tio-D-glucitol spoja prema slijedećoj formuli I, ili njegove farmaceutski prihvatljive soli, ili hidrata spoja ili njegove soli: naznačen time da su Ar', Ar', A i R'-R" kako je definirano u zahtjevu 1, te sadrži korake:
Fatty acids are normally present as mixtures where a fraction of the fatty acids have the functional group possible to chemically react with the intended curing reaction. 
Masne kiseline normalno postoje kao smjese u kojima frakcije masnih kiselina imaju funkcionalne skupine koje mogu kemijski reagirati u predviđenoj reakciji otvrdnjavanja.
The orally disintegrating tablet of clause 27, wherein the orally disintegrating tablet comprises about 0.05-0.3 mg fluticasone. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 14, naznačeno time da tableta sadrži 0.05-0.3 mg budezonida.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, ipconazole, prothioconazole, tebuconazole, epoxiconazole, propiconazole, and cyproconazole. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbomen-5-il)amid, a kao komponentu (B) klorotalonil.
The composition according to claim 1, wherein the retardant is selected from the group consisting of ethylcellulose, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, cellulose acetate phthalate, hydroxypropyl methylcellulose acetate succinate and polymethacrylates. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time, da se usporivač bira između etilceluloze, celuloznog acetata, celuloznog acetat butirata, celuloznog acetat propionata, celuloznog acetat ftalata, hidroksipropil metilceluloza acetat sukcinata i / ili polimetakrilata.
is phenyl, pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl, wherein the pyridyl, pyrazinyl, benzoxazolyl, pyridazinyl, naphthyridinyl or pyrimidinyl is optionally substituted with up to two groups selected from halo, alkoxy, hydroxymethyl and alkyl; and 
Rs je piridil, pirazinil, benzoksazolil, piridazinil, naftiridinil ili pirimidinil, pri čemu piridil, pirazinil, benzoksazolil, piridazinil, naftiridinil ili pirimidinil je proizvoljno supstituiran s do dva supstituenta odabrana iz skupine koju čine halo, alkoksi, hidroksimetil i alkil; i zvonom
combining said aluminium salt, said protein, reactive compound and water to produce said aqueous composition. Aspect 36. 
Postupak za pripremu vodenog pripravka koja sadrži aluminij, reaktivni spoj i protein, pri čemu navedeni postupak sadrži
inhibition of proliferation of a cell expressing CLDN6, 
(1) inhibiciju proliferacije stanice koja eksprimira CLDNG,
The reaction was aged for 30 min. 
Reakcija je odstajala 30 min.
The apparatus of claim 1 wherein said lifter assembly includes a slider (666) mounted on a lifter rod (674), and first and second biasing springs (684, 678), said first biasing spring adapted to move an unlatched slider along said lifter rod in a first direction, said second biasing spring adapted to move said lifter rod and said slider in a second direction opposite said first direction. The apparatus of claim 12 wherein said lifter assembly comprises a rotatable disc (650) adapted to cam said lifter rod in the first direction while compressing said second biasing spring. 
Aparatura u skladu s patentnim zahtjevom 1, naznačena time što navedeni uređaj za dizanje ima jedan dio koji može klizati (666) i koji je montiran na šipku uređaja za dizanje (674), te ima prvu i drugu tlačnu oprugu (684, 678), pri čemu je prva navedena tlačna pruga prilagođena tako, da pomiče nezakvačeni klizač duž navedene šipke uređaja za dizanje u prvom smjeru, a druga tlačna opruga je prilagođena tako da pomiče navedenu šipku uređaja za dizanje i navedeni klizač u drugom smjeru, koji je suprotan navedenom prvom smjeru.
In still yet another preferred embodiment, the evaporated gas phase stream from the devolatization contains at least 30% of lactide, preferably at least 60%, most preferred at least 90%. 
Postupak prema zahtjevu 1 ili 2, naznačen time, da evaporirani tok plinovite faze iz procesa otplinjavanja, sadrži najmanje 30% laktida, poželjno najmanje 60%, a najbolje najmanje 90%.
Authentication method according to any of the preceding claims, wherein the Manager electronic equipment is adapted to manage Manager private and public keys, to store the Manager private key and preferably an Intermediary public key, said keys being used for encrypting and decrypting text messages to and/or from said Intermediary electronic equipment. 
Postupak autentifikacije sukladno bilo kojem od prethodnih Zahtjeva, pri čemu je elektronička oprema Upravitelja prilagođena upravljanju Upraviteljavim privantim 1 javnim kodovima, pohranjivanju Upraviteljevog privatnog koda te po mogućnosti Posrednikova javnog koda, navedeni kodovi koriste se za šifriranje 1 dešifriranje tekstualnih poruka prema i/ili od navedene elektroničke opreme Posrednika,